XL765
| Code | Size | Price |
|---|
| SYN-1137-M100 | 100 mg | Enquire |
Quantity:
| SYN-1137-M001 | 1 mg | £156.00 |
Quantity:
| SYN-1137-M005 | 5 mg | £256.00 |
Quantity:
| SYN-1137-M010 | 10 mg | £385.00 |
Quantity:
| SYN-1137-M050 | 50 mg | £1,234.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
SAR-245409
Appearance:
Solid.
CAS:
1349796-36-6
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C31H29N5O6S/c1-19-9-10-20(15-28(19)42-4)31(37)33-21-11-13-25(14-12-21)43(38,39)36-30-29(34-26-7-5-6-8-27(26)35-30)32-22-16-23(40-2)18-24(17-22)41-3/h5-18H,1-4H3,(H,32,34)(H,33,37)(H,35,36)
InChiKey:
HJSSPYJVWLTYHG-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1349796-36-6. Formula: C31H29N5O6S. MW: 599.7. XL765 is active against class I PI3K (IC(50) = 39, 113, 9 and 43nM for p110alpha, beta, gamma and delta, respectively). XL765 also inhibits DNA-PK (IC(50) = 150nM) and mTOR (IC(50) = 157nM)
Molecular Formula:
C31H29N5O6S
Molecular Weight:
599.7
Package Type:
Plastic Vial
Product Description:
XL765 is active against class I PI3K (IC(50) = 39, 113, 9 and 43nM for p110alpha, beta, gamma and delta, respectively). XL765 also inhibits DNA-PK (IC(50) = 150nM) and mTOR (IC(50) = 157nM)
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 27, 5511 (2008) | Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide: G. Prasad, et al.; Neuro Oncol. 13, 384 (2011)
Related Products
| Product Name | Product Code | Supplier | LY-294002 | AG-CR1-0108 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|